LOGIN
Clinical Meaningfulness Of Response To Tanezumab In Patients With Chronic Low Back Pain
May 2025
Clinical Meaningfulness Of Response To Tanezumab In Patients With Chronic Low Back Pain
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial
Pain Ther . 2022 Dec;11(4):1267-1285.Synopsis
One thousand eight hundred twenty-five patients with chronic low back pain and inadequate response to at least three standard analgesic classes were randomized to receive subcutaneous tanezumab 5 mg (n=407), tanezumab 10 mg (n=407), oral tramadol (n=605), or placebo (n=406). The primary outcome of interest was the patient’s global assessment of low back pain (PGA-LBP). Secondary outcomes included ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.